Novel Gadolinium nanoparticles for Magnetic Resonance Lymphatic Imaging

Introduction Gadolinium (Gd3+) is chelated with diethylenentriaminepentaacetyl (DTPA) to provide contrast in magnetic resonance (MR) imaging to identify pathogenic tissues. Unfortunately, the Gd3+-DTPA complexes approved for clinical use are cleared within a few minutes and do not provide sufficient concentrations or time in lymphoid tissues. Many pathogenic conditions, including the spread of cancer, require high-resolution lymphoid tissue images. Technology description Rodney Ho’s laboratory has designed a potent Gd3+-DTPA-lipid nanoparticle for enhanced MR lymphatic imaging. Subcutaneous administration allows direct access to lymphatic system while the novel formulation is designed to enhance T1 weighted MR signal in the lymph nodes as well as increase the residence time of the contrast agent in the lymphatics. This nanoparticle formulation will allow using a low dose to achieve a high signal-to-noise MR contrast ratio for increasing the metastatic nodal discrimination and allowing for a much wider time frame for imaging. The potentially lower dose of Gd3+
needed for MR contrast may also provide higher safety margin. Business Opportunity The estimated medical MRI procedure volume per year in the US is 27 million with an estimated 64% of procedures employing contrast agents. The world market for medical contrast media for MRI is expected to experience yearly growth rates ranging from 10%
to 20%. Intellectual property position This technology is available for licensing. For more information on this technology contact:
Bolong Cao, Ph.D. Licensing Officer, Invention Licensing 206-685-9348

Type of Offer: Licensing

Next Patent »
« More Medical Devices Patents

Share on      

CrowdSell Your Patent